Thomas Pilgrim1, Pascal Vranckx2, Marco Valgimigli3, Giulio G Stefanini4, Raffaele Piccolo3, Julie Rat5, Martina Rothenbühler5, Stefan Stortecky3, Lorenz Räber3, Stefan Blöchlinger3, Lukas Hunziker3, Sigmund Silber6, Peter Jüni7, Patrick W Serruys8, Stephan Windecker3. 1. Department of Cardiology, Bern University Hospital, Bern, Switzerland. Electronic address: thomas.pilgrim@insel.ch. 2. Department of Cardiac Intensive Care & Interventional Cardiology, Hartcentrum, Hasselt, Belgium. 3. Department of Cardiology, Bern University Hospital, Bern, Switzerland. 4. Division of Clinical and Interventional Cardiology, Humanitas Research Hospital, Rozzano, Milan, Italy. 5. Institute of Social and Preventive Medicine and Clinical Trials Unit, Bern University Hospital, Bern, Switzerland. 6. Heart Center at the Isar, Munich, Germany. 7. Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, and Department of Medicine, University of Toronto, Toronto, Canada. 8. International Centre for Cardiovascular Health, Imperial College, London, United Kingdom.
Abstract
BACKGROUND: We aimed to compare differences in risk and timing of recurrent ischemic events among patients with stable ischemic heart disease (SIHD), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). METHODS: We performed an individual data pooled analysis of 5 randomized controlled all-comer trials including a total of 8,859 patients and investigated the risk and timing of recurrent ischemic events among patients with SIHD (n = 3,543), NSTE-ACS (n = 3,364), and STEMI (n = 1,952) throughout 2 years of follow-up. RESULTS: At 2 years, all-cause mortality was higher among patients with STEMI (6.4%) and NSTE-ACS (6.1%) compared with those with SIHD (4.2%) (STEMI vs SIHD: hazard ratio [HR] 1.40, 95% CI 1.09-1.78, P = .007; NSTE-ACS vs SIHD: 1.40, 95% CI 1.13-1.73, P = .002). In a landmark analysis, the risk of mortality among patients with STEMI compared with those with SIHD was confined to the first 30 days after PCI (HR 6.19, 95% CI 3.15-12.16, P < .001) but was similar between 30 days and 2 years (HR 1.00, 95% CI 0.76-1.33, P = .974) (Pinteraction < .001). Conversely, patients with NSTE-ACS had a higher risk of mortality compared with those with SIHD both within the first 30 days (HR 2.19, 95% CI 1.08-4.47, P = .031) and beyond (HR 1.34, 95% CI 1.07-1.67, P = .012) (Pinteraction < .001). A similar pattern in the differential timing of events was observed for cardiac death. Beyond 30 days, the risk of myocardial infarction was comparable in patients with STEMI and SIHD, whereas the risk in patients with NSTE-ACS was increased (HR 1.65, 95% CI 1.23-2.21, P = .001). CONCLUSION: Whereas patients with NSTE-ACS are at increased risk for death at any time after PCI, the mortality of STEMI patients is higher during the first 30 days after PCI but not thereafter compared with patients with SIHD.
RCT Entities:
BACKGROUND: We aimed to compare differences in risk and timing of recurrent ischemic events among patients with stable ischemic heart disease (SIHD), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). METHODS: We performed an individual data pooled analysis of 5 randomized controlled all-comer trials including a total of 8,859 patients and investigated the risk and timing of recurrent ischemic events among patients with SIHD (n = 3,543), NSTE-ACS (n = 3,364), and STEMI (n = 1,952) throughout 2 years of follow-up. RESULTS: At 2 years, all-cause mortality was higher among patients with STEMI (6.4%) and NSTE-ACS (6.1%) compared with those with SIHD (4.2%) (STEMI vs SIHD: hazard ratio [HR] 1.40, 95% CI 1.09-1.78, P = .007; NSTE-ACS vs SIHD: 1.40, 95% CI 1.13-1.73, P = .002). In a landmark analysis, the risk of mortality among patients with STEMI compared with those with SIHD was confined to the first 30 days after PCI (HR 6.19, 95% CI 3.15-12.16, P < .001) but was similar between 30 days and 2 years (HR 1.00, 95% CI 0.76-1.33, P = .974) (Pinteraction < .001). Conversely, patients with NSTE-ACS had a higher risk of mortality compared with those with SIHD both within the first 30 days (HR 2.19, 95% CI 1.08-4.47, P = .031) and beyond (HR 1.34, 95% CI 1.07-1.67, P = .012) (Pinteraction < .001). A similar pattern in the differential timing of events was observed for cardiac death. Beyond 30 days, the risk of myocardial infarction was comparable in patients with STEMI and SIHD, whereas the risk in patients with NSTE-ACS was increased (HR 1.65, 95% CI 1.23-2.21, P = .001). CONCLUSION: Whereas patients with NSTE-ACS are at increased risk for death at any time after PCI, the mortality of STEMI patients is higher during the first 30 days after PCI but not thereafter compared with patients with SIHD.
Authors: Fan Ye; David Winchester; Michael Jansen; Arthur Lee; Burton Silverstein; Carolyn Stalvey; Matheen Khuddus; Joseph Mazza; Steven Yale Journal: Clin Med Res Date: 2019-06
Authors: Pierre Sabouret; Gilles Lemesle; Anne Bellemain-Appaix; Pierre Aubry; Pier-Paolo Bocchino; Erik Rafflenbeul; Loïc Belle; Jim Nolan; Marco Bernardi; Giuseppe Biondi-Zoccai; Michael P Savage; Maciej Banach; Guillaume Cayla Journal: Arch Med Sci Date: 2022-06-23 Impact factor: 3.707
Authors: Pil Sang Song; Dong Ryeol Ryu; Min Jeong Kim; Ki Hyun Jeon; Rak Kyeong Choi; Jin Sik Park; Young Bin Song; Joo Yong Hahn; Hyeon Cheol Gwon; Youngkeun Ahn; Myung Ho Jeong; Seung Hyuk Choi Journal: Korean Circ J Date: 2018-06 Impact factor: 3.243
Authors: Abhinav Sharma; Christopher P Cannon; William B White; Yuyin Liu; George L Bakris; William C Cushman; Faiez Zannad Journal: J Am Heart Assoc Date: 2018-05-16 Impact factor: 5.501